Transplant Registry Unified Management Program
Japan Wins Exemption for Generics in US-Japan Trade Deal
Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration
Trump’s Most Favored Nation Policy and EU Generics: Recent Developments
Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma
US to Stockpile Critical Drug Ingredients Under Latest Trump Executive Order
Trump; Executive Order; drug ingredients; pharmaceutical supply chain; Strategic Active Pharmaceutical Ingredients Reserve; ASPR; domestic manufacturing; national security; essential medicines
Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days
Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis
Trump Gives Pharma CEOs 60-Day Ultimatum for ‘Most Favored Nation’ Drug Pricing
Trump; pharmaceutical industry; drug pricing; most favored nation policy; executive order; prescription drugs; healthcare policy; Medicaid; tariffs
Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others
Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships
Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy
Vinay Prasad; FDA; departure; Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; conservative criticism; CBER; drug approval controversy; Trump administration
Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal
Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement
Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring
Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments
Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising
Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing